20 news items
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
REGN
16 Jun 24
organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
positive outcome, an even broader range of metastatic PDAC patients may benefit from pelareorep-based therapy
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
outcome, an even broader range of metastatic PDAC patients may benefit from pelareorep-based therapy
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
REGN
11 Jun 24
and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
ABBV
FDMT
REGN
7 Jun 24
such as the risk/benefit balance of fewer anti-VEGF injections compared to the potential for inflammation and steroid use and how this approach differs
hje4t
REGN
31 May 24
-13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2
vt8kajf37mfbri6y942s8u78ehp647tjuln3epws8m4my0x65o5s0u542cct
REGN
31 May 24
and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in phase 3 studies
952infduiwx3b
REGN
31 May 24
clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are key and central drivers of the type 2
lyyw91jesb3pgdcqlrlhkf7adfim0xmfov1hhztktm5t20pt1ujan
REGN
31 May 24
clinical benefit and a decrease in type 2 inflammation in phase 3 studies, establishing that IL-4 and IL-13 are key and central drivers of the type 2
hjwvw8sh2i6 x23tzszwp8kcqu3enlam2coqj65aqadoxkuw523d1r5rh25
REGN
23 May 24
organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement
y7njpcsbm1antzzsubnd8l3fr1skwjpf2fqhvlvj
REGN
20 May 24
) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2
p2m0gvd1romvgbllffztk39kghyb49jf bgwsp9565la
REGN
20 May 24
. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL
o93p6d2n94muo2y5hccg87gcgdqgl98usx76mvppk3ereoy7hgf
REGN
13 May 24
and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase
lqs3pz9mml29bf2y8sw1gb1vx2neru
REGN
8 May 24
organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations
dtd66v4bs8agefp616rzn5quxrssug0ouf5ox 32nsrl3uhd32
REGN
2 May 24
. The GAAP ETR in the first quarter of 2024, compared to the first quarter of 2023, included a higher benefit from stock-based compensation. In the first
r7jxqv1xv0 csri88m3ko
REGN
29 Apr 24
with the aim of extending the time between injections, while maintaining the vision gains, anatomic benefits and safety previously observed with EYLEA
d46lxlx uckqj39qu0cm4f
REGN
22 Apr 24
third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies
teioqhhgoxjp9p47m2nnlmrficxvqvh5xc5f70k94g ix86rywx
AMGN
AZN
REGN
17 Apr 24
at least a 37% reduction in exacerbations for patients with eosinophil counts ≥150 cells/μL and ≥300 cells/μL, potentially offering greater benefits than
evtekzx4kf72xg0r24jyrsinxjbuu2f7ct0
REGN
7 Apr 24
, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government
bdkqwjp9bh4hew3ayiw0jmis1wj7wf094us6sf1 nunbsqkv
REGN
25 Mar 24
private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs
- Prev
- 1
- Next